313 related articles for article (PubMed ID: 34922821)
1. A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective.
Lim HS; Shaw S; Carter AW; Jayawardana S; Mossialos E; Mehra MR
J Heart Lung Transplant; 2022 Feb; 41(2):174-186. PubMed ID: 34922821
[TBL] [Abstract][Full Text] [Related]
2. Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service bridge-to-transplant program for patients with heart failure.
Pulikottil-Jacob R; Suri G; Connock M; Kandala NB; Sutcliffe P; Maheswaran H; Banner NR; Clarke A
J Heart Lung Transplant; 2014 Apr; 33(4):350-8. PubMed ID: 24582838
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
[TBL] [Abstract][Full Text] [Related]
4. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.
Clegg AJ; Scott DA; Loveman E; Colquitt J; Hutchinson J; Royle P; Bryant J
Health Technol Assess; 2005 Nov; 9(45):1-132, iii-iv. PubMed ID: 16303098
[TBL] [Abstract][Full Text] [Related]
5. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.
Long EF; Swain GW; Mangi AA
Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: analysis of the British NHS bridge to transplant (BTT) program.
Clarke A; Pulikottil-Jacob R; Connock M; Suri G; Kandala NB; Maheswaran H; Banner NR; Sutcliffe P
Int J Cardiol; 2014 Feb; 171(3):338-45. PubMed ID: 24424339
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation.
Moreno SG; Novielli N; Cooper NJ
J Heart Lung Transplant; 2012 May; 31(5):450-8. PubMed ID: 22115674
[TBL] [Abstract][Full Text] [Related]
8. Economic Evaluation of Left Ventricular Assist Devices for Patients With End Stage Heart Failure Who Are Ineligible for Cardiac Transplantation.
Chew DS; Manns B; Miller RJH; Sharma N; Exner DV
Can J Cardiol; 2017 Oct; 33(10):1283-1291. PubMed ID: 28941608
[TBL] [Abstract][Full Text] [Related]
9. Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent: The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial.
Goldstein DJ; Naka Y; Horstmanshof D; Ravichandran AK; Schroder J; Ransom J; Itoh A; Uriel N; Cleveland JC; Raval NY; Cogswell R; Suarez EE; Lowes BD; Kim G; Bonde P; Sheikh FH; Sood P; Farrar DJ; Mehra MR
JAMA Cardiol; 2020 Apr; 5(4):411-419. PubMed ID: 31939996
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of left ventricular assist devices as destination therapy in the United Kingdom.
Schueler S; Silvestry SC; Cotts WG; Slaughter MS; Levy WC; Cheng RK; Beckman JA; Villinger J; Ismyrloglou E; Tsintzos SI; Mahr C
ESC Heart Fail; 2021 Aug; 8(4):3049-3057. PubMed ID: 34047072
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure.
Baras Shreibati J; Goldhaber-Fiebert JD; Banerjee D; Owens DK; Hlatky MA
JACC Heart Fail; 2017 Feb; 5(2):110-119. PubMed ID: 28017351
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of continuous-flow left ventricular assist devices.
Neyt M; Van den Bruel A; Smit Y; De Jonge N; Erasmus M; Van Dijk D; Vlayen J
Int J Technol Assess Health Care; 2013 Jul; 29(3):254-60. PubMed ID: 23763844
[TBL] [Abstract][Full Text] [Related]
13. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants.
Mehra MR; Cleveland JC; Uriel N; Cowger JA; Hall S; Horstmanshof D; Naka Y; Salerno CT; Chuang J; Williams C; Goldstein DJ;
Eur J Heart Fail; 2021 Aug; 23(8):1392-1400. PubMed ID: 33932272
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial.
Karason K; Lund LH; Dalén M; Björklund E; Grinnemo K; Braun O; Nilsson J; van der Wal H; Holm J; Hübbert L; Lindmark K; Szabo B; Holmberg E; Dellgren G;
Eur J Heart Fail; 2020 Apr; 22(4):739-750. PubMed ID: 32100946
[TBL] [Abstract][Full Text] [Related]
15. Left Ventricular Assist Devices for Destination Therapy: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2016; 16(3):1-60. PubMed ID: 27026798
[TBL] [Abstract][Full Text] [Related]
16. Early outcomes with durable left ventricular assist device replacement using the HeartMate 3.
Barac YD; Wojnarski CM; Junpaparp P; Jawitz OK; Billard H; Daneshmand MA; Agrawal R; Devore A; Patel CB; Schroder JN; Milano CA
J Thorac Cardiovasc Surg; 2020 Jul; 160(1):132-139.e1. PubMed ID: 31740114
[TBL] [Abstract][Full Text] [Related]
17. Orthotopic heart transplant versus left ventricular assist device: a national comparison of cost and survival.
Mulloy DP; Bhamidipati CM; Stone ML; Ailawadi G; Kron IL; Kern JA
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):566-73; discussion 573-4. PubMed ID: 23246055
[TBL] [Abstract][Full Text] [Related]
18. Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study.
Mehra MR; Salerno C; Cleveland JC; Pinney S; Yuzefpolskaya M; Milano CA; Itoh A; Goldstein DJ; Uriel N; Gulati S; Pagani FD; John R; Adamson R; Bogaev R; Thohan V; Chuang J; Sood P; Goates S; Silvestry SC
Circulation; 2018 Oct; 138(18):1923-1934. PubMed ID: 29807933
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of ventricular assist device therapy as a bridge to transplantation compared with nonbridged cardiac recipients.
Alba AC; Alba LF; Delgado DH; Rao V; Ross HJ; Goeree R
Circulation; 2013 Jun; 127(24):2424-35. PubMed ID: 23697907
[TBL] [Abstract][Full Text] [Related]
20. Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial.
Vidula H; Takeda K; Estep JD; Silvestry SC; Milano C; Cleveland JC; Goldstein DJ; Uriel N; Kormos RL; Dirckx N; Mehra MR
JACC Heart Fail; 2022 Jul; 10(7):470-481. PubMed ID: 35772857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
